23andMe Holding Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for 23andMe Holding.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth19.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

Apr 16
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation

Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%

Mar 02
Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%

We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate

Jul 13
We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate

23andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected

Jun 15
23andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected

23andMe: Disappointing Results Could Mean Potential Acquisition Target

Sep 27

23andMe: Treacherous Path To Profitability

Aug 26

23andMe drops 8% as CFO resigns

Aug 19

23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

Aug 11
23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

23andMe Q1 2023 Earnings Preview

Aug 07

23andMe: Holiday Miracles Not Enough, Growth Path Too Expensive

Jun 15

23andMe: A Genetics Innovator Positioned For Growth

Feb 19

Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues

Feb 18
Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues

23andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive

Nov 21

23andMe Stock: Continued Drug-Development Progress Can Deliver Long-Term Gains

Oct 03

Companies Like 23andMe Holding (NASDAQ:ME) Are In A Position To Invest In Growth

Sep 17
Companies Like 23andMe Holding (NASDAQ:ME) Are In A Position To Invest In Growth

23andMe: New Therapeutic Pipeline And PGS Product Growth Catalyzed By +$696M In SPAC Funding

Jul 19

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as 23andMe Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:ME - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024199-631-146-138N/A
3/31/2024220-667-174-164N/A
12/31/2023248-522-194-183N/A
9/30/2023270-336-158-146N/A
6/30/2023296-327-173-162N/A
3/31/2023299-312-177-165N/A
12/31/2022308-317-167-156N/A
9/30/2022298-315-216-206N/A
6/30/2022277-265-211-195N/A
3/31/2022272-217-181-167N/A
12/31/2021260-215-183-172N/A
9/30/2021259-170-130-119N/A
6/30/2021255-190-90-86N/A
3/31/2021244-184-82-74N/A
3/31/2020305-251-259-186N/A
3/31/2019441-184-126-98N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ME's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if ME's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ME's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ME's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ME's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ME's Return on Equity is forecast to be high in 3 years time


Discover growth companies